Introduction

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue SUPPL. 2, 2004, Pages

  Goldstein, Ellie J C ^a,b  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CILASTATIN; CILASTATIN PLUS IMIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METICILLIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT; EXTENDED SPECTRUM BETA LACTAMASE;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; COMMUNICABLE DISEASE; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG HYDROLYSIS; EDITORIAL; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PNEUMONIA; SIDE EFFECT; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; PENICILLIN RESISTANCE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 3042597425     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh222     Document Type: Editorial

References (10)

1. Chen, D. K., McGeer, A. L., De Azavedo, J. C. et al. (1999). Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. New England Journal of Medicine 341, 233-9.
2. Neuhauser, M. M., Weinstein, R. A., Rydman, R. et al. (2003). Antibiotic resistance among Gram-negative bacilli in US intensive care units. Journal of the American Medical Association 289, 885-8.
3. Shah, P. M. & Isaacs, R. D. (2003). Ertapenem, the first of a new group of carbapenems. Journal of Antimicrobial Chemotherapy 52, 538-42.
4. Solomkin, J. S., Yellin, A. E., Rotstein, O. D. et al. (2003). Results of a double-blind, randomized, comparative trial of ertapenem vs piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Annals of Surgery 237, 235-45.
5. Graham, D., Lucasti, C., Malafaia, O. et al. (2002). Once a day ertapenem versus four daily doses of piperacillin-tazobactam for treatment of complicated skin and skin structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clinical Infectious Diseases 34, 1460-8.
6. Ortiz-Ruiz, G., Caballero-Lopez, J., Friedland, I. et al. (2002). A prospective, multicenter, double-blind, randomized, comparative study to evaluate the safety, tolerability, and efficacy of ertapenem versus ceftriaxone in the treatment of community-acquired pneumonia in adults. Clinical Infectious Diseases 34, 1076-83.
7. Roy, S., Higareda, I., Angel-Muller, E. et al. (2003). Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized double-blind study. Infectious Diseases in Obstetrics and Gynecology 11, 27-37.
8. Tomera, K. M., Burdmann. E. S., Pamo, O. G. et al. (2002). Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrobial Agents and Chemotherapy 46, 2895-900.
9. Jimenz-Cruz, F., Jasovich, A., Cajigas, J. et al. (2002). A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Urology 60, 16-22.
10. Vetter, N., Cambronero-Hernandez, E., Rohlf, J. et al. (2002). A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for treatment of hospitalized adults with community-acquired pneumonia. Clinical Therapeutics 24, 1770-85.